tiprankstipranks
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
US Market

Allogene Therapeutics Stock Forecast & Price Target

800 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
10Ratings
7 Buy
3 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Allogene
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALLO Stock Price Prediction

Average Price Target

$26.75
▲(148.14% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Allogene Therapeutics in the last 3 months. The average price target is $26.75 with a high forecast of $43.00 and a low forecast of $15.00. The average price target represents a 148.14% change from the last price of $10.78.
Highest Price Target$43.00Average Price Target$26.75Lowest Price Target$15.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Guggenheim
Buy
Reiterated
Allogene (ALLO) PT Lowered to $34 at GuggenheimGuggenheim analyst Michael Schmidt lowered the price target on Allogene (NASDAQ: ALLO) to $34.00 (from $35.00) while maintaining a Buy rating.
J.P. Morgan
$20.00
Hold
85.53%
Upside
Reiterated
Allogene Therapeutics (ALLO) Receives a Hold from J.P. Morgan
Truist Financial
Buy
Reiterated
Allogene (ALLO) PT Lowered to $31 at Truist SecuritiesTruist Securities analyst Asthika Goonewardene lowered the price target on Allogene (NASDAQ: ALLO) to $31.00 (from $33.00) while maintaining a Buy rating.
Cowen & Co.
Buy
Reiterated
Cowen reiterates Outperform Rating on Allogene (ALLO), "We Recommend Accumulating ALLO Shares"Cowen analyst Tyler Van Buren reiterated an Outperform rating on Allogene (NASDAQ: ALLO), following resumption of the companys AlloCAR T studies.
Canaccord Genuity
$55.00
Buy
410.20%
Upside
Reiterated
Allogene Therapeutics clinical hold could be lifted shortly, says CanaccordAllogene Therapeutics clinical hold could be lifted shortly, says Canaccord
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ALLO Stock Forecast FAQ

What is ALLO’s average 12-month price target, according to analysts?
Based on analyst ratings, Allogene Therapeutics’s 12-month average price target is $26.75.
    What is ALLO’s upside potential, based on the analysts’ average price target?
    Allogene Therapeutics has 148.14% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALLO a Buy, Sell or Hold?
          Allogene Therapeutics has a conensus rating of Moderate Buy which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Allogene Therapeutics’s price target?
            The average price target for Allogene Therapeutics is $26.75. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $43.00 ,the lowest forecast is $15.00. The average price target represents 148.14% Increase from the current price of $10.78.
              What do analysts say about Allogene Therapeutics?
              Allogene Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis